GGHC
CRBP icon

Gilder Gagnon Howe & Co’s Corbus Pharmaceuticals CRBP Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,328
Closed -$513K – 254
2024
Q2 		$513K Buy
+11,328
New +$476K 0.01% 231
2016
Q4 		– Sell
-2,495
Closed -$508K – 270
2016
Q3 		$508K Buy
+2,495
New +$310K 0.01% 206

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Gilder Gagnon Howe & Co's CRBP Position: Q3 2024 in Review

Gilder Gagnon Howe & Co sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 11,328 shares — an estimated $513K sold.

Gilder Gagnon Howe & Co first reported a position in CRBP in Q3 2016 and held it in 2 quarters. The position peaked at $513K in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Gilder Gagnon Howe & Co reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 11,328 Corbus Pharmaceuticals shares in Q3 2024, an estimated $513K.
  • Gilder Gagnon Howe & Co first reported a position in Corbus Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Corbus Pharmaceuticals position peaked at $513K in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2024, filed 14 Nov 2024.